IceCure Medical (ICCM) Cash from Financing Activities (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Cash from Financing Activities data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 38.06% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $16.8 million, a 88.61% increase from a year earlier, with the FY2025 full-year figure at $15.8 million, up 72.35% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.5 million, down from $3.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for ICCM reached as high as $13.6 million in Q4 2022 and fell as low as $68000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $3.8 million across 5 years, with a median of $2.8 million in 2024.
• Across the five-year window, Cash from Financing Activities tumbled 99.5% in 2023 and surged 1519.12% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $13.6 million in 2022, then tumbled by 99.5% to $68000.0 in 2023, then jumped by 1519.12% to $1.1 million in 2024, then soared by 237.87% to $3.7 million in 2025, then declined by 4.92% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $3.5 million in Q1 2026, $3.7 million in Q4 2025, and $7.5 million in Q3 2025.